<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02948309</url>
  </required_header>
  <id_info>
    <org_study_id>131016</org_study_id>
    <secondary_id>2014-004552-64</secondary_id>
    <nct_id>NCT02948309</nct_id>
  </id_info>
  <brief_title>Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer</brief_title>
  <acronym>MISTRAL</acronym>
  <official_title>Mistletoe Therapy in Primary &amp; Recurrent Inoperable Pancreatic Cancer. A Phase III Prospective Randomized Double Blinded Multicenter Parallel Group Placebo Controlled Clinical Trial on Overall Survival and Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Witten/Herdecke</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regional Cancer Centre Stockholm Gotland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stiftelsen Konung Gustaf V:s Jubileumsfond för cancerforskning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Signe &amp; Ane Gyllenbergs Stiftelse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ekhagastiftelsen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dagmar Ferbs Minnesfond</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancerforskningsfonden i Norrland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Immunpathologisches Labor, University Tübingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Sjöberg Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study a mistletoe preparation (Iscador Qu) is added to standard therapy in inoperable&#xD;
      pancreatic cancer in order to evaluate effect on overall survival and health-related quality&#xD;
      of life. Half of participants will take subcutaneous injections with mistletoe in addition to&#xD;
      standard therapy (palliative chemotherapy or best supportive care); the other half will&#xD;
      receive a placebo and standard therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Extracts from European mistletoe (Viscum album L.) have been used as complementary cancer&#xD;
      therapy since the 1920s. To date over 160 clinical studies on mistletoe in cancer therapy&#xD;
      have been conducted with varying quality; the therapy is still controversial.&#xD;
&#xD;
      Best evidence is found for increase of health-related quality of life (HRQoL) and reduction&#xD;
      of side effects of conventional therapies (chemotherapy, radiation) in breast cancer&#xD;
      patients. Mistletoe treatment is described as safe and well tolerated. There are some&#xD;
      clinical studies supporting the use of mistletoe extract in the management of late stage&#xD;
      cancer.&#xD;
&#xD;
      Statistically significant effects on overall survival (OS) and HRQoL in pancreatic cancer&#xD;
      patients have recently been shown in a randomized open label trial in Serbia investigating&#xD;
      the addition of mistletoe extract to best supportive care. The results are questioned because&#xD;
      patients knew what kind of treatment they received.&#xD;
&#xD;
      Mistletoe extracts are usually administered subcutaneously. They contain a multitude of&#xD;
      substances with immune modulatory and cytotoxic or - in animal studies - antitumorigenic,&#xD;
      anti-metastatic and antiangiogenic effects.&#xD;
&#xD;
      This trial investigates whether there is a beneficial effect of mistletoe extracts on OS and&#xD;
      HRQoL in pancreatic cancer patients receiving standard treatment (palliative chemotherapy or&#xD;
      best supportive care).&#xD;
&#xD;
      Inclusion has started at 4 study centers (2 more centers are waiting for participation). And&#xD;
      participants are randomized 1:1 to mistletoe treatment (Iscador Qu®) given in increasing&#xD;
      dosage from 0,01mg to 20 mg or placebo injections subcutaneously 3 times /week.&#xD;
      Stratification will be performed for received oncological treatment (palliative chemotherapy&#xD;
      or best supportive care). At 7 visits in 9 months, participants fill in the validated EORTC&#xD;
      QLQ-C30 (QLO=quality of life questionnaire) and PAN-26 (PAN=pancreas) quality of life&#xD;
      questionnaires. Body weight, use of cancer-related medicines, substitution of nutrition,&#xD;
      adverse events need of supportive care and inpatient care are measured. To be able to assess&#xD;
      more dimensions of quality of life than possible with questionnaires, a qualitative sub-study&#xD;
      with interviews on about 30 participants in this trial is performed in month 3. A 2nd&#xD;
      substudy has been added november 2016 to elucidate the systemic effects of mistletoe therapy&#xD;
      and to explore potential prognostic and predictive biomarkers (anticipated n=100).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>End of study (estimated 3 years)</time_frame>
    <description>OS defined as time from randomization to death for any reason</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life questionnaire EORTC QLQ-C30</measure>
    <time_frame>At 7 visits during study (9 months)</time_frame>
    <description>Evaluation according to EORTC QLQ-C30 Scoring Manual</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life questionnaire EORTC PAN -26</measure>
    <time_frame>At 7 visits during study (9 months)</time_frame>
    <description>Evaluation according to EORTC PAN-26 Scoring Manual</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight in kilograms, height in meters, BMI in kg/m^2</measure>
    <time_frame>At 7 visits during study (9 months)</time_frame>
    <description>Body weight, Body Mass Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corticosteroid use in milligrams betamethasone per day and indication (appetite, chemotherapy, nausea, pain, general wellbeing, other: specified)</measure>
    <time_frame>At 7 visits during study (9 months)</time_frame>
    <description>Corticosteroid use and indication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of visits of homecare team per week</measure>
    <time_frame>At 7 visits during study (9 months)</time_frame>
    <description>Costs for supportive care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of oral nutrition support per week (number used per day)</measure>
    <time_frame>At 7 visits during study (9 months)</time_frame>
    <description>Costs for supportive care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of symptom relieving medication in mg/day (painkillers, antiemetic and anxiolitic medication)</measure>
    <time_frame>At 7 visits during study (9 months)</time_frame>
    <description>Costs for supportive care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemotherapy use (number of cycles first line, second line, ..) and dose reduction in%</measure>
    <time_frame>At 7 visits during study (9 months)</time_frame>
    <description>Costs for supportive care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of parenteral nutrition infusions per week</measure>
    <time_frame>At 7 visits during study (9 months)</time_frame>
    <description>Costs for supportive care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of unplanned inpatient care</measure>
    <time_frame>At 7 visits during study (9 months)</time_frame>
    <description>Costs for inpatient care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events (AE)</measure>
    <time_frame>Through study completion (9 months)</time_frame>
    <description>Safety</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">290</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Mistletoe extract (Iscador Qu)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fermented aqueous extract of Viscum album ssp album (L.) (mistletoe) = Iscador Qu, subcutaneous use 3 injections/week; dose escalation from 0,01mg - 20mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>isotonic saline solution, subcutaneous use 3 injections/week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mistletoe extract (Iscador Qu)</intervention_name>
    <description>1ml subcutaneous injection 3 times/week, dose escalation 0,01mg - 20mg</description>
    <arm_group_label>Mistletoe extract (Iscador Qu)</arm_group_label>
    <other_name>Fermented aqueous extract of Viscum album ssp album (L.)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1ml subcutaneous injection 3 times/week</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Isotonic saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Signed written informed consent&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Inoperable locally advanced or metastatic pancreatic cancer or relapse of pancreatic&#xD;
             cancer.&#xD;
&#xD;
               -  Primary diagnosis: if histology is not clinically achievable diagnosis is to be&#xD;
                  confirmed according to local practice sufficient for diagnosis and choice of&#xD;
                  therapy (such as CA19-9 (=cancer antigen 19-9) and CT).&#xD;
&#xD;
               -  Relapse: histology (not required) or diagnosis according to local practice such&#xD;
                  as clinical signs and/or imaging and/or CA19-9.&#xD;
&#xD;
          -  ECOG ( Eastern Cooperative Oncology Group) performance status 0-2 (see table in&#xD;
             section 12.14 )&#xD;
&#xD;
          -  Adequate negative pregnancy test and adequate contraception (where appropriate)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Life expectancy less than 4 weeks&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Neuroendocrine tumors of the pancreas (NET)&#xD;
&#xD;
          -  Current use of interferon, G-CSF (granulocyte colony-stimulating factor) and thymus&#xD;
             preparations&#xD;
&#xD;
          -  Symptomatic brain edema due to brain metastases&#xD;
&#xD;
          -  Known hypersensitivity to mistletoe-containing products&#xD;
&#xD;
          -  Current use of mistletoe extract preparations in any form&#xD;
&#xD;
          -  Chronic granulomatous disease or active autoimmune disease or autoimmune disease with&#xD;
             immunosuppressive treatment&#xD;
&#xD;
          -  Medical, psychiatric, cognitive or other conditions that may compromise the patient´s&#xD;
             ability to understand the patient information, give informed consent, comply with the&#xD;
             study protocol or complete the study (e.g. needle phobia).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annika Bergquist, Ass Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Gastrocentrum Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathrin Wode, MD</last_name>
    <phone>+46 8 123 142 61</phone>
    <email>kathrin.wode@sll.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roger Henriksson, Prof</last_name>
    <phone>+46-70 588 99 33</phone>
    <email>roger.henriksson@umu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kathrin Wode</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathrin Wode, MD</last_name>
      <phone>+46-8-12314261;+46-707-374261</phone>
      <email>kathrin.wode@sll.se</email>
    </contact>
    <contact_backup>
      <last_name>Berit Sunde, PhD</last_name>
      <phone>+46858586721</phone>
      <email>berit.sunde@sll.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Tröger W, Galun D, Reif M, Schumann A, Stanković N, Milićević M. Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial. Dtsch Arztebl Int. 2014 Jul 21;111(29-30):493-502, 33 p following 502. doi: 10.3238/arztebl.2014.0493.</citation>
    <PMID>25142075</PMID>
  </reference>
  <reference>
    <citation>Tröger W, Galun D, Reif M, Schumann A, Stanković N, Milićević M. Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival. Eur J Cancer. 2013 Dec;49(18):3788-97. doi: 10.1016/j.ejca.2013.06.043. Epub 2013 Jul 24.</citation>
    <PMID>23890767</PMID>
  </reference>
  <reference>
    <citation>Horneber MA, Bueschel G, Huber R, Linde K, Rostock M. Mistletoe therapy in oncology. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD003297. doi: 10.1002/14651858.CD003297.pub2. Review.</citation>
    <PMID>18425885</PMID>
  </reference>
  <reference>
    <citation>Kienle GS, Glockmann A, Schink M, Kiene H. Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. J Exp Clin Cancer Res. 2009 Jun 11;28:79. doi: 10.1186/1756-9966-28-79. Review.</citation>
    <PMID>19519890</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 13, 2016</study_first_submitted>
  <study_first_submitted_qc>October 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2016</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Kathrin Wode</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Primary diagnosis</keyword>
  <keyword>Relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Viscum album peptide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The trial results will be submitted for publication in relevant medical journals</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

